

CITATION REPORT

List of articles citing

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base

DOI: 10.1016/j.eururo.2012.11.015
European Urology, 2013, 63, 823-9.

Source: <https://exaly.com/paper-pdf/55182756/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
185	Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. 2013 , 14, 109-15		13
184	Radical locoregional therapy for bladder cancer: underutilized, or unsuitable in many?. <i>European Urology</i> , 2013 , 63, 830-1	10.2	
183	Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. <i>Eur Urol</i> 2013;63:823-9. <i>European Urology</i> , 2013 , 64, e84-5	10.2	
182	Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer. 2013 , 23, 429-34		2
181	Current approaches to the management of bladder cancer in older patients. 2014 , e250-6		6
180	Uptake of neoadjuvant chemotherapy for invasive bladder cancer. 2014 , 8, e294-5		4
179	Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. <i>BJU International</i> , 2014 , 114, 719-26	5.6	97
178	Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1429-43	3.5	1
177	Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1108-15	2.8	23
176	[Concomitant chemoradiotherapy for muscle-invasive bladder cancer: current knowledge, controversies and future directions]. 2014 , 18, 779-89		0
175	Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 206	5.3	13
174	Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 1048-56	4	57
173	Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. <i>European Urology</i> , 2014 , 66, 120-37	10.2	190
172	The economics of bladder cancer: costs and considerations of caring for this disease. <i>European Urology</i> , 2014 , 66, 253-62	10.2	311
171	Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. <i>Cancer</i> , 2014 , 120, 3089-96	6.4	63
170	Challenging treatment decision-making in older urologic cancer patients. <i>World Journal of Urology</i> , 2014 , 32, 299-308	4	16
169	Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. 2014 , 83, 75-80		94

168	Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 326-31	4	51
167	Management of muscle-invasive bladder cancer in the elderly. 2015 , 25, 459-67		12
166	Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. 2015 , 10, 205		18
165	Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?. 2015 , 25, 476-82		15
164	Imaging muscle-invasive and metastatic urothelial carcinoma. 2015 , 25, 441-8		18
163	Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. 2015 , 9, 236-41		7
162	The Role of Population-Based Observational Research in Bladder Cancer. 2015 , 1, 123-131		1
161	Bladder cancer in the elderly patient: challenges and solutions. 2015 , 10, 939-49		31
160	Outcomes of radical cystectomy in potential candidates for bladder preservation therapy. 2015 , 85, 869-75		15
159	Terapia trimodal en c�ncer urotelial de vejiga. 2015 , 24, 166-171		
158	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2015 , 67, 241-9	10.2	178
157	Organ preservationWill data translate into reality for bladder cancer patients?. <i>Clinical Oncology</i> , 2015 , 27, 133-5	2.8	1
156	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 204.e1-7	2.8	28
155	Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility. <i>Cancer</i> , 2015 , 121, 681-7	6.4	20
154	Exploring the 3 A� of cystectomy access to care for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 105-7	2.8	3
153	Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice. <i>Urologic Clinics of North America</i> , 2015 , 42, 181-7, viii	2.9	7
152	Langzeitergebnisse von Patienten mit muskelinvasiven Harnblasenkarzinomen nach multimodaler, organerhaltender Therapie. 2015 , 191, 288-290		
151	Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e153-8	3.3	10

150	Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35	5.5	101
149	Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. 2015 , 95, 387-96		62
148	Organ-sparing surgery in urology: partial cystectomy. 2015 , 25, 111-5		19
147	Nonclinical Factors Predict Selection of Initial Observation for Renal Cell Carcinoma. 2015 , 86, 892-9		14
146	Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. <i>European Urology</i> , 2015 , 67, 165-170	10.2	159
145	Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. <i>BJU International</i> , 2015 , 115, 722-7	5.6	18
144	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). 2015 , 93, 36-49		15
143	Treatment of Muscle-Invasive Bladder Cancer in Older Patients. 2016 , 35, e228-33		4
142	Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. <i>Nature Reviews Urology</i> , 2016 , 13, 440-1	5.5	8
141	Urothelial carcinoma management in elderly or unfit patients. 2016 , 14, 1-20		34
140	Words of Wisdom. Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. <i>European Urology</i> , 2016 , 69, 757-8	10.2	
139	Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 468-74	2.8	2
138	Using big data for quality assessment in oncology. <i>Journal of Comparative Effectiveness Research</i> , 2016 , 5, 309-19	2.1	6
137	Concurrent chemoradiotherapy in elderly patients with muscle-invasive bladder cancer: A single-center experience. 2016 , 3, 73-76		2
136	Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. <i>Cancer Medicine</i> , 2016 , 5, 1098-107	4.8	4
135	Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 432.e15-23	2.8	29
134	Summary and Recommendations from the National Cancer Institute® Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. 2016 , 2, 165-202		22
133	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 683-90	4	41

132	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3529-3536	2.2	47
131	Utilisation of preoperative imaging for muscle-invasive bladder cancer: a population-based study. <i>BJU International</i> , 2016 , 117, 430-8	5.6	11
130	Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 82-8	3.3	24
129	Evolving concepts in muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2016 , 34, 1-2	4	4
128	Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 262-70	2.8	8
127	Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. <i>World Journal of Urology</i> , 2016 , 34, 3-11	4	16
126	Bladder Cancer. 2016 , 1096-1120.e6		0
125	Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy. <i>BJU International</i> , 2017 , 119, 128-134	5.6	14
124	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017 , 71, 952-960	10.2	153
123	Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 115-122	4	35
122	Adjuvant Radiotherapy Use by US Radiation Oncologists After Radical Cystectomy for Muscle-invasive Bladder Cancer. <i>Clinical Oncology</i> , 2017 , 29, 429-435	2.8	8
121	Bladder Cancer. 2017 , 481-496		
120	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017 , 35, 1729-1736	4	7
119	Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. <i>Cancer</i> , 2017 , 123, 3524-3531	6.4	22
118	Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. <i>World Journal of Urology</i> , 2017 , 35, 1879-1884	4	1
117	Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2017 , 123, 4337-4345	6.4	45
116	Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation. 2017 , 6, 387-395		2
115	Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 670.e15-670.e21	2.8	14

114	Zwischenergebnisse der PROMETRICS 2011 nach fünf Jahren. <i>Uro-News</i> , 2017 , 21, 37-41	0	
113	Increased Use of Cystectomy in Patients 75 and Older: A Contemporary Analysis of Survival and Perioperative Outcomes From the National Cancer Database. 2017 , 100, 72-78		16
112	Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. <i>European Urology</i> , 2017 , 71, 729-737	10.2	81
111	Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>European Urology</i> , 2018 , 73, 810-811	10.2	2
110	A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 293-305 ^{2.8}		22
109	Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine. 2018 , 22, 236-240		2
108	Comparative effectiveness of robot-assisted vs. open radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 88.e1-88.e9	2.8	35
107	The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 851-857	4	12
106	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 213-218	3.3	10
105	Bladder-Sparing Treatments. 2018 , 467-505		
104	Whole Versus Partial Bladder Radiation: Use of an Image-guided Hypofractionated IMRT Bladder-preservation Protocol. 2018 , 41, 107-114		12
103	Bladder Cancer in the Elderly. <i>European Urology</i> , 2018 , 73, 51-52	10.2	18
102	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. <i>European Urology</i> , 2018 , 73, 40-50	10.2	69
101	Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. 2018 , 4, 568-571		5
100	Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-based Study Evaluating Health Care Disparities in the United States According to Insurance Status. 2018 , 41, 476-484		10
99	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. 2018 , 41, 953-959		9
98	Radiosensitization by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity. 2018 , 17, 381-392		23
97	Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2018 , 199, 407-415	2.5	23

96	Perioperative outcomes of robot-assisted laparoscopic partial cystectomy. 2018 , 12, 223-228		5
95	Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States. 2018 , 2, pky075		8
94	Bladder Cancer Survivorship. 2018 , 19, 111		39
93	Toward Biomarker-Informed Trimodality Therapy (TMT) Approaches for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 1417-1419	4	
92	Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. 2018 , 19, 108		12
91	A Festschrift in Honor of Edward M. Messing, MD, FACS. 2018 , 4, S1-S43		
90	Trimodal therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 1219-1229		15
89	Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis. <i>World Journal of Urology</i> , 2018 , 36, 1997-2008	4	15
88	Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors. 2018 , 35, 409-421		2
87	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 470.e19-470.e29	2.8	4
86	Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2018 , 8, 8360	4.9	14
85	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. <i>European Urology Oncology</i> , 2018 , 1, 83-90	6.7	34
84	Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 877-885	2.8	0
83	How to guide the selection of patients for trimodality therapy: the case for tumor immune and stromal signature. <i>Translational Andrology and Urology</i> , 2019 , 8, S329-S331	2.3	
82	Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 402-407	3.3	18
81	Palliative Radiation Therapy in Bladder Cancer-Importance of Patient Selection: A Retrospective Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 389-393	4	12
80	Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e995-e1002	3.3	17
79	Treatment delays for muscle-invasive bladder cancer. <i>Cancer</i> , 2019 , 125, 1973-1975	6.4	3

78	Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 44-51	2.2	47
77	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019 , 21, 24	6.3	13
76	The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer. <i>Translational Andrology and Urology</i> , 2019 , 8, S514-S516	2.3	1
75	Commentary: underutilization of curative-intent therapy for patients with muscle-invasive bladder cancer in Sweden mimics the United States. <i>Translational Andrology and Urology</i> , 2019 , 8, S542-S545	2.3	2
74	Barriers to Neoadjuvant Chemotherapy before Radical Cystectomy at a Single Referral Center in South Florida. <i>Urology Practice</i> , 2019 , 6, 317-321	0.8	
73	The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 1767-1772	4	2
72	Safeguarding Autonomy of Patients With Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 81-83	4	2
71	Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>JAMA Surgery</i> , 2019 , 154, 185-186	5.4	1
70	Radical radiotherapy in older patients with muscle invasive bladder cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 292-297	3.6	4
69	Population-based validation of the National Comprehensive Cancer Network's recommendations for baseline imaging for bladder cancer: a case for routine baseline bone scan?. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 157-163	2.1	1
68	National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. <i>European Urology Oncology</i> , 2020 , 3, 343-350	6.7	4
67	Carcinoma of the Bladder. 2020 , 1382-1400.e4		0
66	Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents. <i>Urologic Clinics of North America</i> , 2020 , 47, 119-128	2.9	2
65	Occupational disparities in bladder cancer survival: A population-based cancer registry study in Japan. <i>Cancer Medicine</i> , 2020 , 9, 894-901	4.8	6
64	Prognosis of patients with muscle invasive bladder cancer who are intolerable to receive any anti-cancer treatment. <i>Cancer Treatment and Research Communications</i> , 2020 , 24, 100195	2	9
63	Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy. <i>Radiotherapy and Oncology</i> , 2020 , 151, 190-199	5.3	1
62	Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. <i>Scientific Reports</i> , 2020 , 10, 15822	4.9	5
61	Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 ,	2.8	

60	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 551-561	3.5	9
59	Bladder-sparing treatment options in localized muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 179-188	3.5	1
58	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. <i>Practical Radiation Oncology</i> , 2020 , 10, e378-e387 ^O	2.8	3
57	Impact of age on bladder cancer management practices: a general population study. <i>Acta Oncologica</i> , 2020 , 59, 462-466	3.2	1
56	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1043-1053	3.6	22
55	Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2020 , 27, 236-243	2.3	2
54	Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1760-1762	2.2	5
53	Die Grenzen der Zystektomie. <i>Uro-News</i> , 2020 , 24, 34-39	0	
52	Setting the stage for bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 209-212	2.8	2
51	Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy. <i>Clinical Oncology</i> , 2021 , 33, 46-49	2.8	3
50	Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2020 , 22, 3	5.4	1
49	Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 412-424	4	7
48	Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 299.e7-299.e14	2.8	1
47	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 953-963	4	5
46	Epidemiology of Bladder Cancer: Trends and Disparities. 2021 , 1-12		
45	Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?. <i>Translational Andrology and Urology</i> , 2021 , 10, 356-373	2.3	1
44	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. <i>The Korean Journal of Urological Oncology</i> , 2021 , 19, 30-39	0.1	
43	MR-Guided Adaptive Radiotherapy for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 637591	5.3	10

42	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes Following Radical Cystectomy. <i>Journal of Urology</i> , 2021 , 205, 400-406	2.5	2
41	The Growth of Integrated Care Models in Urology. <i>Urologic Clinics of North America</i> , 2021 , 48, 223-232	2.9	
40	Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. <i>Nature Communications</i> , 2021 , 12, 2776	17.4	15
39	Real World Outcomes of Patients with Bladder Cancer: Effectiveness Versus Efficacy of Modern Treatment Paradigms. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 597-612	3.1	0
38	A Tailored Radiation Therapy Strategy for Older Patients With Localized Bladder Cancer Not Eligible for Curative Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 425-428	4	
37	Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER). <i>Clinical Oncology</i> , 2021 , 33, e251-e256	2.8	2
36	Overcoming the Chasm Between Evidence and Routine Practice for Bladder Cancer; Just a Quixotic Notion?. <i>Clinical Oncology</i> , 2021 , 33, e274-e284	2.8	0
35	Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans. <i>European Urology Open Science</i> , 2021 , 30, 1-10	0.9	2
34	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 40, 62.e1-62.e1	2.8	
33	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 528-547	2.8	
32	Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? Opinion: Yes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017 , 43, 184-187	1.8	6
31	Radical cystectomy: a review of techniques, developments and controversies. <i>Translational Andrology and Urology</i> , 2020 , 9, 3073-3081	2.3	5
30	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020 , 72, 1-12	4.4	7
29	Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?. <i>Indian Journal of Urology</i> , 2017 , 33, 111-117	0.8	4
28	Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer. <i>Investigative and Clinical Urology</i> , 2020 , 61, 565-572	1.9	6
27	Patterns of care in patients with muscle-invasive bladder cancer - a retrospective cohort study. <i>Wspolczesna Onkologia</i> , 2016 , 20, 341-3	1	2
26	Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation.. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100836	3.3	
25	The Role of Radiation in Urological Malignancies. 2015 , 41-51		

24	Integrating chemotherapy and radiotherapy for bladder cancer. 221-232		
23	Harnblasenkarzinom beim alten und geriatrischen Patienten. 2017 , 1-12		
22	Radiotherapy for the Treatment of Muscle-Invasive Bladder Cancer. 2018 , 83-89		
21	Harnblasenkarzinom beim alten und geriatrischen Patienten. 2018 , 461-472		
20	Outcomes of patients undergoing radiation therapy for bladder cancer. <i>Bladder</i> , 2018 , 5, e37	2	
19	Treating Elderly Patients With Muscle-Invasive Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 783-790	7.3	3
18	Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013. <i>Asian Journal of Urology</i> , 2021 ,	2.7	
17	Partial cystectomy for muscle-invasive bladder cancer: a review of the literature. <i>Translational Andrology and Urology</i> , 2020 , 9, 2938-2945	2.3	7
16	Prospective evaluation of definitive chemoradiotherapy with volumetric modulated arc therapy in patients with muscle invasive carcinoma of urinary bladder. <i>Wspolczesna Onkologia</i> , 2020 , 24, 177-182	1	
15	Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.. <i>BJU International</i> , 2022 ,	5.6	
14	[Geriatric assessment and treatment of nonmetastatic muscle-invasive bladder cancer in patients over 75 years of age. Retrospective and multicentric study of 121 cases].. <i>Progres En Urologie</i> , 2022 ,	0.9	
13	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy.. <i>Cancers</i> , 2022 , 14,	6.6	2
12	Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer.. <i>Oncology Letters</i> , 2022 , 23, 126	2.6	
11	Management of bladder cancer in older patients.. <i>Japanese Journal of Clinical Oncology</i> , 2021 ,	2.8	2
10	Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.. <i>World Journal of Urology</i> , 2022 , 1	4	
9	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 ,	2.8	0
8	Bladder cancer, inflammaging and microbiomes. <i>Nature Reviews Urology</i> ,	5.5	0
7	Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort study. <i>Acta Oncologica</i> , 1-7	3.2	

- 6 Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting. **2022**, 14, 3896
- 5 Partial cystectomy: Review of a single center experience from 2004 to 2019. **2022**, ○
- 4 Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer. **2023**, 33, 56-61 ○
- 3 Integrated molecular analyses of an interferon- γ -based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. **2022**, 8, e12102 ○
- 2 Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer. **2023**, ○
- 1 Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients. ○